Long-term Access Program (LAP) of Mepolizumab for Subjects who Participated in Study MEA115921

Trial Identifier: 116841
Sponsor: GlaxoSmithKline
Start Date: April 2015
Primary Completion Date: February 2023
Study Completion Date: February 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Belgium Bruxelles, Belgium, 1070
Canada, ON Hamilton, ON, Canada, L8N 4A6
France Bron, France, 69677
France Marseille, France, 13915
France Montpellier cedex, France, 34295
France Paris, France, 75014
France Saint-Priest en Jarez, France, 42270
France Suresnes, France, 92151
Germany Bad Bramstedt, Germany, 24576
Germany Freiburg, Germany, 79106
Germany Fulda, Germany, 36043
Germany Jena, Germany, 07740
Germany Kirchheim, Germany, 73230
Japan Kanagawa, Japan, 252-0392
Japan Miyagi, Japan, 980-8574
United Kingdom Cambridge, United Kingdom, CB2 0QQ
United Kingdom Leicester, United Kingdom, LE3 9QP
United Kingdom Portsmouth, United Kingdom, PO6 3LY
United States, CO Denver, CO, United States, 80206
United States, MA Boston, MA, United States, 02118-2307
United States, MA Boston, MA, United States, 02215
United States, MD Bethesda, MD, United States, 20892
United States, MO St Louis, MO, United States, 63110
United States, NY New York, NY, United States, 10021
United States, OH Cleveland, OH, United States, 44195
United States, OK Oklahoma City, OK, United States, 73131
United States, PA Philadelphia, PA, United States, 19104
United States, TN Germantown, TN, United States, 38119
United States, UT Salt Lake City, UT, United States, 84107
United States, UT St George, UT, United States, 84770
United States, VA Abingdon, VA, United States, 24210
United States, WA Bellevue, WA, United States, 98004